Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

E. A. Stein, R. P. Giugliano, M. J. Koren, F. J. Raal, E. M. Roth, R. Weiss, D. Sullivan, S. M. Wasserman, R. Somaratne, J. B. Kim, J. Yang, T. Liu, M. Albizem, R. Scott, M. S. Sabatine
  • European Heart Journal, March 2014, European Society of Cardiology
  • DOI: 10.1093/eurheartj/ehu085

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1093/eurheartj/ehu085

In partnership with: